

University of Wollongong

## Research Online

---

Faculty of Science, Medicine and Health -  
Papers: part A

Faculty of Science, Medicine and Health

---

2009

### Serotonin 2A receptor and its association with the pathology of schizophrenia

Chao Deng

*University of Wollongong, [chao@uow.edu.au](mailto:chao@uow.edu.au)*

Kai Kang

*The Ninth Hospital of Chongqing, China*

Qing Wang

*Sun Yat-Sen University of Medical Sciences*

Follow this and additional works at: <https://ro.uow.edu.au/smhpapers>



Part of the [Medicine and Health Sciences Commons](#), and the [Social and Behavioral Sciences Commons](#)

---

#### Recommended Citation

Deng, Chao; Kang, Kai; and Wang, Qing, "Serotonin 2A receptor and its association with the pathology of schizophrenia" (2009). *Faculty of Science, Medicine and Health - Papers: part A*. 1388.  
<https://ro.uow.edu.au/smhpapers/1388>

Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library: [research-pubs@uow.edu.au](mailto:research-pubs@uow.edu.au)

---

## Serotonin 2A receptor and its association with the pathology of schizophrenia

### Abstract

Dear Editor: Accumulated evidence suggests that serotonin 2A (5-HT<sub>2A</sub>) receptors are implicated in the pathology of schizophrenia. However the results remain inconclusive, particularly in the case of binding studies using postmortem tissue. We agree with Dean's comment that our recent paper (Kang et al., 2009) reported a decrease in the density of [<sup>3</sup>H] ketanserin binding to the 5-HT<sub>2A</sub> receptors in the superior temporal gyrus (STG), which supported earlier findings in the planum temporal cortex (Pralong et al., 2000), despite Burnet et al. reporting previously that there was no change in [<sup>3</sup>H] ketanserin binding in the STG in schizophrenia (Burnet et al., 1996).....

### Keywords

CMMB

### Disciplines

Medicine and Health Sciences | Social and Behavioral Sciences

### Publication Details

Deng, C., Kang, K., Wang, Q. & Huang, X. (2009). Serotonin 2A receptor and its association with the pathology of schizophrenia. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 33 (8), 1585-1586.

## **SEROTONIN 2A RECEPTOR AND ITS ASSOCIATION WITH THE PATHALOGY OF SCHIZOPHRENIA**

**Chao Deng<sup>1,2,\*</sup>, Kai Kang<sup>1,3</sup>, Qing Wang<sup>1,4</sup>, Xu-Feng Huang<sup>1,2</sup>**

1. Centre for Translational Neuroscience, School of Health Sciences, University of Wollongong, Wollongong, NSW 2522, Australia
2. Schizophrenia Research Institute, Sydney, NSW 2010, Australia
3. The Ninth Hospital of Chongqing, Beibei, Chongqing 400700, P. R. China
4. Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong 510630, P.R. China

### **\*Corresponding Author:**

Chao Deng, School of Health Sciences, University of Wollongong,  
Wollongong, NSW 2522, Australia

Tel: +61 2 4221 4934

Fax: +61 2 4221 5945

Email: [chao@uow.edu.au](mailto:chao@uow.edu.au)

Dear Editor:

Accumulated evidence suggests that serotonin 2A (5-HT<sub>2A</sub>) receptors are implicated in the pathology of schizophrenia. However the results remain inconclusive, particularly in the case of binding studies using postmortem tissue. We agree with Dean's comment that our recent paper (Kang et al., 2009) reported a decrease in the density of [<sup>3</sup>H] ketanserin binding to the 5-HT<sub>2A</sub> receptors in the superior temporal gyrus (STG), which supported earlier findings in the planum temporal cortex (Pralong et al., 2000), despite Burnet et al. reported previously that there was no change in [<sup>3</sup>H] ketanserin binding in the STG in schizophrenia (Burnet et al., 1996). The controversy has also been the case in studies on [<sup>3</sup>H] ketanserin binding density in the dorsolateral prefrontal cortex and hippocampus in schizophrenia, even when reports have arisen from the same laboratory (Scarr et al., 2004, Matsumoto et al., 2005) and using tissue from same cohort of subjects (Dean and Hayes, 1996, Dean et al., 1996). Recently, Dean and his colleagues have provided evidence to show that confounding [<sup>3</sup>H] ketanserin binding results in the dorsolateral prefrontal cortex of schizophrenia subjects were due to the employment of different methodologies, whereby a decrease in [<sup>3</sup>H] ketanserin binding in the dorsolateral prefrontal cortex in schizophrenia could only be detected by binding experiments on tissue sections and in crude homogenate, not on washed membranes (Dean et al., 2008). Dean and colleagues tried to extend this finding to the whole CNS (Dean et al., 2008), however this extension was not supported by their results in the STG and hippocampus (Pralong et al., 2000, Scarr et al., 2004, Matsumoto et al., 2005). Using tissue from the same cohort of subjects for studies in the dorsolateral prefrontal cortex, Dean and colleagues observed a decrease in the density of 5-HT<sub>2A</sub> receptors in the STG of

schizophrenia subjects using [ $^3\text{H}$ ] ketanserin binding techniques in both tissue sections and washed membranes (Pralong et al., 2000); findings that were opposite to those reported in the dorsolateral prefrontal cortex (Dean and Hayes, 1996, Dean et al., 1996). Even more interesting, the  $B_{\max}$  measured by both binding methods used in the STG were significantly correlated ( $r^2 = 0.501$ ,  $p=0.024$ ) (Pralong et al., 2000). On the other hand, decreased [ $^3\text{H}$ ] ketanserin binding in the hippocampus was reported in one of their studies (Scarr et al., 2004) but not the other (Matsumoto et al., 2005), despite using the same binding method (ie: in tissue sections). Unfortunately, these opposing results appear to be omitted in Dean's comments and earlier paper (Dean et al., 2008). Therefore, if these results are correct, caution should be given if extending the findings reported in the dorsolateral prefrontal cortex to other CNS regions.

As various neurotransmitter receptor systems (eg. dopamine D2, GABA<sub>A</sub>, 5-HT<sub>2A</sub> etc. receptors) are involved in the pathology of schizophrenia (Wong and Van Tol, 2003), it is important to understand how these neurotransmitter systems interacted. We recognized that Dean has made a contribution in revealing the relationships among dopamine D2, GABA<sub>A</sub>, 5-HT<sub>2A</sub>, and muscarinic M1 receptor alterations in the dorsolateral prefrontal cortex in schizophrenia (Dean, 2001). Our recent studies of the pathological changes of GABA<sub>A</sub>, 5-HT<sub>2A</sub>, and muscarinic M1 receptors in the STG (Deng and Huang, 2005, Deng and Huang, 2006, Deng et al., 2007, Kang et al., 2009) provide an opportunity for us to explore the relationships among these receptors in the STG and their possible roles in the pathology of schizophrenia. Regarding the present study, we would like to clarify that, schizophrenia and control data were combined due to the relative low sample size (8

schizophrenia subjects and 8 controls), and Spearman's correlation test was employed to assess the relationships between the bindings of various receptors (Kang et al., 2009). We would also take this opportunity to correct a typographical error in the correlation between 5-HT<sub>2A</sub> and GABA<sub>A</sub> receptors (corrected to  $r=-0.47$ ,  $p=0.066$ ). These correlation data represent possible interactions between these receptors, and we agree with Dean's comments that one should be cautious when interpreting these relationship results. Further studies to identify the mechanisms for the interactions between various neurotransmitter receptors would largely contribute to revealing the pathology of schizophrenia.

## Reference

- Burnet, P. W., Eastwood, S. L. and Harrison, P. J., 1996. 5-HT<sub>1A</sub> and 5-HT<sub>2A</sub> receptor mRNAs and binding site densities are differentially altered in schizophrenia. *Neuropsychopharmacology*. 15, 442-455.
- Dean, B., 2001. A predicted cortical serotonergic/cholinergic/GABAergic interface as a site of pathology in schizophrenia. *Clinical & Experimental Pharmacology & Physiology*. 28, 74-78.
- Dean, B., Crossland, N., Boer, S. and Scarr, E., 2008. Evidence for altered post-receptor modulation of the serotonin 2a receptor in schizophrenia. *Schizophrenia Research*. 104, 185-197.
- Dean, B. and Hayes, W., 1996. Decreased frontal cortical serotonin<sub>2A</sub> receptors in schizophrenia. *Schizophrenia Research*. 21, 133-139.
- Dean, B., Hayes, W., Opeskin, K., Naylor, L., Pavey, G., Hill, C., Keks, N. and Copolov, D. L., 1996. Serotonin<sub>2</sub> receptors and the serotonin transporter in the schizophrenic brain. *Behavioural Brain Research*. 73, 169-175.
- Deng, C., Han, M. and Huang, X.-F., 2007. No changes in densities of cannabinoid receptors in the superior temporal gyrus in schizophrenia. *Neuroscience Bulletin*. 23, 341-347.
- Deng, C. and Huang, X.-F., 2005. Decreased density of muscarinic receptors in the superior temporal gyrus in schizophrenia. *Journal of Neuroscience Research*. 81, 883-890.
- Deng, C. and Huang, X.-F., 2006. Increased density of GABA<sub>A</sub> receptors in the superior temporal gyrus in schizophrenia. *Experimental Brain Research*. 168, 587-590.
- Kang, K., Huang, X.-F., Wang, Q. and Deng, C., 2009. Decreased density of serotonin 2A receptors in the superior temporal gyrus in schizophrenia-A postmortem

- study. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*. 33, 867-871.
- Matsumoto, I., Inoue, Y., Iwazaki, T., Pavey, G. and Dean, B., 2005. 5-HT<sub>2A</sub> and muscarinic receptors in schizophrenia: a postmortem study. *Neuroscience Letters*. 379, 164-168.
- Pralong, D., Tomaskovic-Crook, E., Opeskin, K., Copolov, D. and Dean, B., 2000. Serotonin(2A) receptors are reduced in the planum temporale from subjects with schizophrenia. *Schizophrenia Research*. 44, 35-45.
- Scarr, E., Pavey, G., Copolov, D. and Dean, B., 2004. Hippocampal 5-hydroxytryptamine receptors: abnormalities in postmortem brain from schizophrenic subjects. *Schizophrenia Research*. 71, 383-392.
- Wong, A. H. C. and Van Tol, H. H. M., 2003. Schizophrenia: from phenomenology to neurobiology. *Neuroscience & Biobehavioral Reviews*. 27, 269-306.